Dinara Begimbetova

Dr. Dinara Begimbetova

Center for Life Sciences, National Laboratory Astana, Nazarbayev University, Nur-Sultan, Astana, Kazakhstan
orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 January 2021 in Clinical Endoscopy
Verified
Journal Article
Open access
PDF file
AZAlma Zhylkaidarova
Alma Zhylkaidarova
Dilyara KaidarovaDilyara Kaidarova
Dilyara Kaidarova
KBKanat Batyrbekov
Kanat Batyrbekov
OSOxana Shatkovskaya
Oxana Shatkovskaya
DBDinara Begimbetova
Dinara Begimbetova
We carried out an analysis of the total incidence of colon cancer throughout Kazakhstan. Retrospectively, according to the regional reports on endoscopic screening, the study showed an increase in the age-related incidence of colorectal cancer (CRC) cases from 2004-2008 to 2009-2014. The peak of morbidity in both periods was noted in the age category of >70 years. The indicators of the territorial distribution of CRC incidence make it possible to divide the regions into areas with low or high rates of CRC. Specific indicators showed newly diagnosed cases of CRC stages I, II, III, and IV in 2004-2018. The incidence rates of stages I and II showed a two-fold increase (35%-67.4%) and the incidence of stage IV showed a decline from 19.3% to 13.1% and of stage III from 45.7% to 19.5% from 2004 to 2018, respectively. An analysis of CRC incidence throughout Kazakhstan showed an increase in the overall incidence. Since population-based CRC screening was introduced in 2011, the morbidity was found to increase for stages I and II.

3 July 2014 in Ecotoxicology
Verified
Journal Article
Closed access
PDF file
SKSaule Kolumbayeva
Saule Kolumbayeva
DBDinara Begimbetova
Dinara Begimbetova
TSTamara Shalakhmetova
Tamara Shalakhmetova
TSTimur Saliev
Timur Saliev
ALAnna Lovinskaya
Anna Lovinskaya
BZBenazir Zhunusbekova
Benazir Zhunusbekova

1 July 2017 in Journal of Thermal Biology
Verified
Journal Article
Closed access
TSTimur Saliev
Timur Saliev
LFLoreto B Feril
Loreto B Feril
DBDinara Begimbetova
Dinara Begimbetova
DBDinara Baiskhanova
Dinara Baiskhanova
AKAnton Klodzinskyi
Anton Klodzinskyi
Katsuro TachibanaKatsuro Tachibana
Katsuro Tachibana

1 November 2022 in Cells
Verified
Journal Article
Open access
PDF file
ABAgata Natasza Burska
Agata Natasza Burska
BIBayansulu Ilyassova
Bayansulu Ilyassova
ADAruzhan Dildabek
Aruzhan Dildabek
MKMedina Khamijan
Medina Khamijan
DBDinara Begimbetova
Dinara Begimbetova
DSDos Djurmakhanbet Sarbassov
Dos Djurmakhanbet Sarbassov
The turn-on mutations of the KRAS gene, coding a small GTPase coupling growth factor signaling, are contributing to nearly 25% of all human cancers, leading to highly malignant tumors with poor outcomes. Targeting of oncogenic KRAS remains a most challenging task in oncology. Recently, the specific G12C mutant KRAS inhibitors have been developed but with a limited clinical outcome because they acquire drug resistance. Alternatively, exploiting a metabolic breach of KRAS-mutant cancer cells related to a glucose-dependent sensitivity to oxidative stress is becoming a promising indirect cancer targeting approach. Here, we discuss the use of a vitamin C (VC) acting in high dose as an oxidative “Trojan horse” agent for KRAS-mutant cancer cells that can be potentiated with another oxidizing drug arsenic trioxide (ATO) to obtain a potent and selective cytotoxic impact. Moreover, we outline the advantages of VC’s non-natural enantiomer, D-VC, because of its distinctive pharmacokinetics and lower toxicity. Thus, the D-VC and ATO combination shows a promising path to treat KRAS-mutant cancers in clinical settings.

30 November 2020 in Medicina
Verified
Journal Article
Open access
PDF file
TSTimur Saliev
Timur Saliev
DBDinara Baiskhanova
Dinara Baiskhanova
Dmitriy BeznoskoDmitriy Beznosko
Dmitriy Beznosko
DBDinara Begimbetova
Dinara Begimbetova
BUBauyrzhan Umbayev
Bauyrzhan Umbayev
DPdainius pavalkis
dainius pavalkis
Background and objectives: The aim of the study was to scrutinize the ability of epsilon-aminocaproic acid (EACA) to prevent radiation-induced damage to human cells. Materials and Methods: Human peripheral blood mononuclear cells (PBMCs) were exposed to ionizing radiation at three low doses (22.62 mGy, 45.27 mGy, and 67.88 mGy) in the presence of EACA at the concentration of 50 ng/mL. Results: EACA was able to prevent cell death induced by low-dose X-ray radiation and suppress the formation of reactive oxygen species (ROS). EACA also demonstrated a capacity to protect DNA from radiation-induced damage. The data indicated that EACA is capable of suppression of radiation-induced apoptosis. Comparative tests of antioxidative activity of EACA and a range of free radical scavengers showed an ability of EACA to effectively inhibit the generation of ROS. Conclusions: This study showed that the pretreatment of PBMCs with EACA is able to protect the cells from radiation-elicited damage, including free radicals’ formation, DNA damage, and apoptosis.

Verified
Journal Article
Open access
PDF file
BIBayansulu Ilyassova
Bayansulu Ilyassova
NRNargiz Rakhimgerey
Nargiz Rakhimgerey
SRSaule Rakhimova
Saule Rakhimova
NSNazerke Satvaldina
Nazerke Satvaldina
ADAsset Daniyarov
Asset Daniyarov
DSDos Djurmakhanbet Sarbassov
Dos Djurmakhanbet Sarbassov
Cancer cells can sustain survival independently of exogenous growth factors. To investigate their adaptation to serum deprivation, we analyzed transcriptomic responses in two cancer cell lines. Transcriptome analysis revealed upregulation of mRNAs encoding cholesterol biosynthesis enzymes. This was a critical adaptive response, as a pharmacological inhibition of the pathway with statin triggered a robust apoptotic cell death accompanied by generation of a mitochondrial reactive oxygen species. The mechanistic target of rapamycin complex 1 (mTORC1), a master regulator of cell growth, is known to be engaged in controlling lipid biosynthesis. We detected the high polysomal and preribosomal peaks not only in serum-containing medium but also under serum deprivation, indicating a high rate of protein synthesis and ribosomal biogenesis independent of serum. In addition, the inhibition of mTOR kinase activity substantially reduced polysome abundance, with a more pronounced effect in serum-deprived cancer cells. Notably, the mTOR kinase inhibition also prevented the upregulation of the cholesterol synthesis enzyme that established a direct link between mTOR activity, protein synthesis, and cholesterol biosynthesis. Together, our results show that cancer cells adapt to serum withdrawal by activating the cholesterol synthesis pathway through mTOR-dependent regulation of gene expression and protein synthesis, underscoring a critical mechanism of survival under serum withdrawal.